BioMarin Announces Third Quarter 2018 Results
SAN RAFAEL, Calif., Oct. 25, 2018 /PRNewswire/ --
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2018 2017 % Change 2018 2017 % Change
Total Revenues $
391.7 $
334.1 17 $
1,138.0 $
955.3 19
% %
Vimizim Net Product Revenues 123.3 90.3 37 368.0 299.3 23
% %
Kuvan Net Product Revenues 113.3 105.8 7 321.4 300.1 7
% %
Naglazyme Net Product Revenues 103.1 72.1 43 269.2 238.4 13
% %
Aldurazyme Net Product Revenues 27.6 22.4 23 117.7 61.7 91
% %
Brineura Net Product Revenues 9.9 3.1 219 27.7 3.4 715
% %
Palynziq Net Product Revenues 4.1 n/a 4.1 n/a
GAAP Net Loss $
(12.6) $
(12.5) $
(73.6) $
(65.7)
GAAP Net Loss per Share - Basic and $
(0.07) $
(0.07) $
(0.42) $
(0.38)
Diluted
Non-GAAP Income (1) $
60.7 $
7.8 $
101.8 $
68.7
September 30, December
31,
2018 2017
Cash, cash equivalents and investments $
1,648.3 $
1,781.7
(1) Non-GAAP Income is defined by the
Company as reported GAAP Net
Income (Loss), excluding net
interest expense, provision for
(benefit from) income taxes,
depreciation expense, amortization
expense, stock-based compensation
expense, contingent consideration
expense and, in certain periods,
certain other specified items.
Refer to Non-GAAP Information
beginning on page 9 of this press
release for a complete discussion
of the Company's Non-GAAP
financial information and
reconciliations to the comparable
information reported under
Generally Accepted Accounting
Principles in the United States
(US GAAP).
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (BioMarin or the Company) today announced financial results for the third quarter ended September 30, 2018. The financial results that follow represent a comparison of the third quarter of 2018 to the third quarter of 2017. Total revenues were $391.7 million for the quarter ended September 30, 2018 compared to $334.1 million for the quarter ended September 30, 2017, an increase of 17%. GAAP Net Loss for the quarter ended September 30, 2018 was $12.6 million, or $0.07 loss per basic and diluted share compared to GAAP Net Loss of $12.5 million, or $0.07 loss per basic and diluted share for the quarter ended September 30, 2017.
Net product revenues for the third quarter of 2018 were $386.3 million, compared to $298.8 million in the third quarter of 2017. The increase in net product revenues was attributed to the following:
-- Vimizim: increased by $33.0 million, or 37%, due primarily to government
ordering patterns in certain countries and an increase in the number of
commercial patients;
-- Brineura: contributed $6.8 million to increased net product revenues,
primarily attributed to new patients initiating therapy as the product
launched in mid-2017;
-- Kuvan: increased $7.5 million, or 7%, primarily driven by an increase in
the number of commercial patients in North America;
-- Naglazyme: increased $31.0 million, or 43%, primarily due to government
ordering patterns in certain countries and new patients initiating
therapy in Europe;
-- Palynziq: received approval from the Food and Drug Administration (FDA)
in May 2018, with commercial sales launching in the third quarter of
2018. Palynziq sales in the third quarter of 2018 were primarily
attributed to conversion of clinical patients in the U.S.; and
-- Aldurazyme: increased $5.2 million, or 23%, primarily as a result of
increased volume.
The increase in GAAP Net Loss was primarily due to the following:
-- Higher research and development (R&D) expense for the expansion of our
clinical programs related to vosoritide and valoctocogene roxaparvovec
and higher selling, general and administrative (SG&A) expense in support
of the U.S. commercial launch of Palynziq and European pre-launch
activities, the continued commercial expansion of Kuvan and patient
advocacy activities related to our valoctocogene roxaparvovec product
candidate and continued commercial expansion of Brineura, partially
offset by:
-- Increased gross profit primarily driven by increased net product
revenues across all of our commercial products other than Firdapse.
Non-GAAP Income for the third quarter of 2018 was $60.7 million, compared to Non-GAAP Income of $7.8 million in the third quarter of 2017. The increase in Non-GAAP income in the third quarter of 2018 is primarily attributed to increased gross profit from revenues, offset by higher R&D and SG&A expenses.
As of September 30, 2018, BioMarin had cash, cash equivalents and investments totaling approximately $1.6 billion, as compared to $1.8 billion on December 31, 2017. On October 15, 2018, our 0.75% senior subordinated convertible notes matured and were settled with a combination of $375.0 million in cash for the full principal amount, issuance of common stock for the conversion value in excess of the principal, and cash in lieu of any fractional shares.
Commenting on third quarter results, Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, said, "BioMarin's achievements this year give us potential for significant growth in 2019. In the second quarter we received FDA approval of Palynziq, an important new therapy that helps address a significant unmet need in adults with phenylketonuria (PKU) who have been unable to control their blood Phe levels with current treatment options. We also filed for approval of Palynziq in Europe and expect to hear the status of that application in the first half of 2019. The market opportunity with Palynziq is significant and we have been very encouraged by the level of enthusiasm from the PKU community since product launch in July. At the end of the third quarter, 124 U.S. commercial patients were being treated with Palynziq and we are on track to have 250 to 300 U.S. commercial patients by year-end."
"In clinical development, we provided two years of clinical data with the 6e13 vg/kg dose of valoctocogene roxaparvovec gene therapy for severe Hemophilia A from the ongoing Phase 1/2 study in at the World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, Scotland during the second quarter. The updated data demonstrated the elimination of need for prophylaxis and no spontaneous bleeds for two years. In addition, we amended the protocol for the global GENEr8-1 (Phase 3) pivotal study to evaluate superiority compared to the current standard of care. The number of participants has been increased to 130 and we now anticipate completing enrollment during the second quarter of 2019. Another significant development in the year was the publication of draft guidance from the FDA for hemophilia products. We are encouraged by the considerations included in the guidance document, particularly in relation to the potential for an accelerated approval, and believe it may be pertinent to valoctocogene roxaparvovec if our program results are supportive."
Mr. Bienaimé continued, "Our annual Research and Development Day will be held in New York City on November 7, 2018 where we look forward to showcasing our capabilities from pre-clinical work through manufacturing. Specifically, we look forward to providing a 42-month update on vosoritide for the treatment of achondroplasia as well as preclinical data with our next gene therapy product candidate, BMN 307, for the treatment of phenylketonuria. With approximately $1.5 billion in revenues anticipated for the full year 2018, two potentially $1.0 billion-plus late-stage clinical product opportunities, and a growing early-stage pipeline, BioMarin is poised for significant growth."
As presented August 2, 2018 Full-Year Financial Guidance ( in millions, except %)
Item 2018 Guidance
---
Total Revenues
$1,470 to $1,530
Kuvan Net Product Revenues
$440 to $480
Naglazyme Net Product Revenues
$325 to $355
Vimizim Net Product Revenues
$460 to $500
Brineura Net Product Revenues
$35 to $55
Palynziq Net Product Revenues*
$10 to $14
Cost of Sales (% of Total
Revenues) 20.0% to 21.0%
Research and Development Expense
$680 to $710
Selling, General and Admin.
Expense
$575 to $615
GAAP Net Loss
$(115) to $(165)
Non-GAAP Income **
$100 to $140
*Guidance for Palynziq not
previously provided
**All Financial Guidance items are
calculated based on US GAAP with
the exception of Non-GAAP Income.
Refer to Non-GAAP Information
beginning on page 9 of this press
release for a complete discussion
of the Company's Non-GAAP
financial information and
reconciliations to the comparable
GAAP reported information.
Select Agenda Items at Upcoming R&D Day, November 7, 2018 in New York City:
Vosoritide for Achondroplasia:
-- Drug Development Considerations in Achondroplasia, presented by Ron
Rosenfeld, M.D., Professor and Chair (emeritus) of Pediatrics, Oregon
Health & Science University and Former Senior Vice President and Medical
Director, Lucile Packard Foundation for Children's Health
-- 42-Month Vosoritide Data Update, presented by Jonathan Day, M.B.B.S.,
Ph.D., Executive Medical Director, Clinical Science, BioMarin
PKU Gene Therapy Data and Program update; Research & Development Pipeline Deep Dive:
-- Genetics, Genomics and the Future of Us presented by Lon Cardon, Ph.D.,
Senior Vice President and Chief Scientific Officer, BioMarin
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A:
-- Regulatory Path Considerations, presented by Geoff Nichol, M.B., Ch.B.,
M.B.A., Senior Vice President, Chief Medical Officer and Head of Global
Clinical Development, BioMarin
-- Considerations for Manufacture of AAV-Based Gene Therapy Products,
presented by Robert Baffi, Ph.D., M.B.A., Executive Vice President,
Technical Operations, BioMarin
Regulatory Policy Advances at the Food and Drug Administration:
-- The Evolving Regulatory Landscape and Significance of Patient
Engagement, presented by Adora Ndu, Pharm.D., J.D., Executive Director
and Head of Global Regulatory Policy, Research, and Patient Engagement,
BioMarin
Key Program Highlights
-- Palynziq for phenylketonuria: With the approval in May 2018 of Palynziq
in the United States, an injection to reduce blood Phe concentrations in
adult patients with phenylketonuria, BioMarin added the seventh
commercial product to its portfolio. Palynziq, a PEGylated recombinant
phenylalanine ammonia lyase enzyme, is the first approved enzyme
substitution therapy to target the underlying cause of PKU by helping
the body to break down Phe. The Company expects to learn the status of
its Marketing Authorization Application for Palynziq in Europe in the
first half of 2019.Upon approval of Palynziq in May 2018, the Company
said it would report two key metrics related to the U.S. commercial
launch beginning in the third quarter of 2018. The first metric provides
the number of clinics that have prescribed Palynziq. At the end of the
third quarter, 50 unique clinics had prescribed Palynziq. The second
metric, the number of naïve and clinical trial patients who are
receiving reimbursed, commercial treatment with Palynziq totaled 124 at
the end of the third quarter. Of the 124 patients, 81 were from the
clinical trial study and 43 were formerly naïve to treatment. In
addition, the Company anticipates between 250 to 300 adult PKU patients
will be on treatment with Palynziq by year-end 2018, including 153
subjects from the clinical studies.
-- Valoctocogene roxaparvovec gene therapy for hemophilia A: In May 2018,
the Company updated the protocol for the Phase 3 GENEr8-1 study
evaluating the 6e13 vg/kg dose and has powered the study to evaluate
superiority to the current standard of care, Factor VIII prophylaxis.
The Phase 3 GENEr8-1 study will now include 130 participants (an
increase of 90 from the original 40) and is expected to be fully
enrolled in the second quarter of 2019.Based on recent draft guidelines
published by the FDA on the development of gene therapy products for the
treatment of hemophilia, BioMarin believes that an accelerated approval
path forward may be an option with valoctocogene roxaparvovec. In
addition, if the Company pursues an accelerated approval, it will inform
investors of that decision in the second half of 2019.
-- Vosoritide for achondroplasia: On November 7, 2018, the Company intends
to provide a 42-month update at R&D Day on vosoritide, an analog of
C-type natriuretic peptide (CNP). It is being studied in children with
achondroplasia. The program includes four distinct areas of focus to
support global approval. Currently enrolling, the global Phase 3 study
is a randomized, placebo-controlled study of vosoritide in approximately
110 children with achondroplasia ages 5-14 for 52 weeks. The study will
be followed by a subsequent open-label extension. Children in this study
will have completed a minimum six-month baseline study to determine
their respective baseline growth velocity prior to entering the Phase 3
study. In addition, the Company expects to have over 5 years of clinical
data from the long-term, open-label Phase 2 program to corroborate
maintenance of effect.
-- Tralesinidase alfa (formerly referred to as BMN 250) for MPS IIIB
(Sanfilippo Syndrome, Type B): In September 2018, the Company provided
an update at the Society for the Study of Inborn Errors of Metabolism
(SSIEM) meeting from the Phase 1/2 trial with tralesinidase alfa. Of
the seven subjects who have been treated with the 300 mg/kg weekly dose,
heparan sulfate levels were normalized in the brain fluid. All subjects
also experienced normalization of the enlargement of their liver and
spleen. Development Quotient (DQ), a measure of cognitive function
normalized to age, was also monitored. Five of the seven subjects have
experienced encouraging trends in brain function based on DQ measures.
Other Ongoing Clinical Development Programs:
-- BMN 290 for Friedreich's Ataxia: In 2017, BioMarin announced that it had
selected as its next clinical drug development candidate, BMN 290, a
selective chromatin modulation therapy intended for treatment of
Friedreich's ataxia. Currently, there are no approved disease modifying
therapies for Friedreich's ataxia. The Company is currently conducting
additional pre-clinical work on BMN 290 and could potentially file an
investigational new drug (IND) application in the first half of 2019
based on the outcome of those data.
-- Gene therapy product candidate for phenylketonuria (PKU): As previously
announced, the Company expects to submit an investigational new drug
(IND) application for a gene therapy product for the treatment of PKU in
the second half of 2019. In preclinical models, BioMarin's PKU gene
therapy product candidate demonstrated sustained, normalized Phe levels
in an ongoing study and out to 60 weeks at the last observation. The
product candidate is an AAV vector containing the DNA sequence that
codes for the phenylalanine hydroxylase enzyme that is deficient in
people with PKU.
BioMarin will host a conference call and webcast to discuss third quarter 2018 financial results today, Thursday, October 25, 2018 at 4:30 p.m. ET. This event can be accessed on the investor section of the BioMarin website at www.biomarin.com.
U.S. /Canada Dial-in Number: Replay Dial-in Number:
866.502.9859 855.859.2056
---
International Dial-in Number: Replay International Dial-in
574.990.1362 Number: 404.537.3406
---
Conference ID: 6487064
Conference ID: 6487064
---
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of several approved products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com.
Forward-Looking Statements
This press release and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: the expectations of Total Revenues, Net Product Revenues and expenses for BioMarin's commercial products, GAAP Net Loss, Non-GAAP Income (Loss) and other specified income statement guidance; the financial performance of BioMarin as a whole; BioMarin's potential for growth, the anticipated number of U.S. commercial patients treated with Palynziq by year-end; BioMarin's commercial prospects, including its expected $1.0 billion-plus late-stage clinical product opportunities; the timing of (i) decisions by regulators, including the European Commission's decision regarding BioMarin's Marketing Authorization Application for Palynziq, (ii) BioMarin's clinical studies and trials, (iii) completion of enrollment of those studies and trials including enrollment in BioMarin's Phase 3 program with valoctocogene roxaparvovec, and (iv) announcements of data from those studies and trials, including BioMarin's Phase 3 program and Phase 1/2 study with valoctocogene roxaparvovec; the ongoing Phase 2 and Phase 3 studies of vosoritide and the Phase 1/2 study of tralesinidase alfa (formerly referred to as BMN 250); the continued clinical development and commercialization of BioMarin's commercial products and product candidates, including BioMarin's plans to potentially file an IND for BMN 290 in the first half of 2019 and an IND for its new gene therapy candidate for the treatment of PKU in the second half of 2019; the estimated number of adults with PKU who will be on treatment with Palynziq by the end of the year; the possible approval and commercialization of BioMarin's product candidates. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: BioMarin's success in the commercialization of its commercial products; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials, BioMarin's ability to successfully manufacture its commercial products and product candidates; the content and timing of decisions by the FDA, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products; actual sales of BioMarin's commercial products; the introduction of generic versions of BioMarin's commercial products, in particular generic versions of Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission (SEC), including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 as such factors may be updated by any subsequent reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin(®), Brineura(®), Firdapse(®), Kuvan(®), Naglazyme(® ), Palynziq(®) and Vimizim(®) are registered trademarks of BioMarin Pharmaceutical Inc., or its affiliates. Aldurazyme(®) is a registered trademark of BioMarin/Genzyme LLC.
Contact:
Investors:
Media:
Traci McCarty Debra Charlesworth
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558
(415) 455-7451
BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
September 30, 2018 and December 31, 2017
(In thousands of U.S. dollars, except share and per share amounts)
September 30, December 31,
2018 2017
(1) (2)
ASSETS (unaudited)
Current assets:
Cash and cash equivalents $
882,184 $
598,028
Short-term investments 561,192 797,940
Accounts receivable, net 384,343 261,365
Inventory 508,482 475,775
Other current assets 71,652 74,036
Total current assets 2,407,853 2,207,144
Noncurrent assets:
Long-term investments 204,883 385,785
Property, plant and equipment, net 924,033 896,700
Intangible assets, net 494,687 517,510
Goodwill 197,039 197,039
Deferred tax assets 429,194 399,095
Other assets 37,565 29,852
Total assets $
4,695,254 $
4,633,125
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities $
378,226 $
401,921
Short-term convertible debt, net 374,230 360,949
Short-term contingent acquisition consideration 86,204 53,648
Total current liabilities 838,660 816,518
Noncurrent liabilities:
Long-term convertible debt, net 826,119 813,521
Long-term contingent acquisition consideration 58,160 135,318
Other long-term liabilities 57,370 59,105
Total liabilities 1,780,309 1,824,462
Stockholders' equity:
Common stock, $0.001 par value: 500,000,000 shares
authorized; 178 176
177,902,788 and 175,843,749 shares issued and
outstanding, respectively.
Additional paid-in capital 4,620,817 4,483,220
Company common stock held by Nonqualified Deferred
Compensation Plan (13,415) (14,224)
Accumulated other comprehensive loss (2,160) (22,961)
Accumulated deficit (1,690,475) (1,637,548)
Total stockholders' equity 2,914,945 2,808,663
Total liabilities and stockholders' equity $
4,695,254 $
4,633,125
(1) As of January 1, 2018, the
Company adopted the requirements
of Accounting Standards
Codification 606, Revenue from
Contracts with Customers (ASC
606), using the modified
retrospective method, and as a
result, there is a lack of
comparability of certain amounts
to the prior periods presented.
(2) December 31, 2017 balances were
derived from the audited
Consolidated Financial
Statements included in the
Company's Annual Report on Form
10-K for the year ended December
31, 2017, filed with the U.S.
Securities and Exchange
Commission on February 26, 2018.
BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three and Nine Months Ended September 30, 2018 and 2017
(In thousands of U.S. dollars, except per share amounts)
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2018 (1) 2017 2018 (1) 2017
REVENUES:
Net product revenues $
386,320 $
298,752 $
1,123,205 $
916,868
Royalty and other revenues 5,386 35,396 14,793 38,473
Total revenues 391,706 334,148 1,137,998 955,341
OPERATING EXPENSES:
Cost of sales 78,893 59,480 240,245 165,791
Research and development 161,408 154,103 520,938 442,145
Selling, general and administrative 148,566 130,532 440,182 394,056
Intangible asset amortization and contingent 18,580 3,760 42,009 26,096
consideration
Gain on sale of intangible assets (20,000)
Total operating expenses 407,447 347,875 1,223,374 1,028,088
LOSS FROM OPERATIONS (15,741) (13,727) (85,376) (72,747)
Equity in the loss of BioMarin/Genzyme LLC (468) (253) (507) (996)
Interest income 6,338 3,976 17,141 10,031
Interest expense (12,131) (10,884) (35,918) (31,043)
Other income, net 2,589 267 5,266 4,282
LOSS BEFORE INCOME TAXES (19,413) (20,621) (99,394) (90,473)
Benefit from income taxes (6,793) (8,094) (25,833) (24,823)
NET LOSS $
(12,620) $
(12,527) $
(73,561) $
(65,650)
NET LOSS PER SHARE, BASIC AND DILUTED $
(0.07) $
(0.07) $
(0.42) $
(0.38)
Weighted average common shares outstanding, basic 177,481 175,103 176,767 174,071
and dilutive
(1) As of January 1, 2018, the
Company adopted the requirements
of ASC 606 using the modified
retrospective method, and as a
result, there is a lack of
comparability of certain amounts
to the prior periods presented.
Non-GAAP Information
The results presented in this press release include both GAAP information and Non-GAAP information. As used in this release, Non-GAAP Income (Loss) is defined by the Company as GAAP Net Loss excluding net interest expense, provision for (benefit from) income taxes, depreciation expense, amortization expense, stock-based compensation expense, contingent consideration expense and, in certain periods, certain other specified items, as detailed below when applicable. In addition, BioMarin includes in this press release the effects of these adjustments on certain components of GAAP Net Loss for each of the periods presented. In this regard, Non-GAAP Income (Loss) and its components, including Non-GAAP Cost of Sales, Non-GAAP Research and Development expenses, Non-GAAP Selling, General and Administrative expense, Non-GAAP Intangible Asset Amortization and Contingent Consideration, Non-GAAP Gain on the Sale of Intangible Asset and Non-GAAP Benefit From Income Taxes are statement of operations line items prepared on the same basis as, and therefore components of, the overall Non-GAAP measures.
BioMarin regularly uses both GAAP and Non-GAAP results and expectations internally to assess its financial operating performance and evaluate key business decisions related to its principal business activities: the discovery, development, manufacture, marketing and sale of innovative biologic therapies. Because Non-GAAP Income (Loss) and its components are important internal measurements for BioMarin, the Company believes that providing this information in conjunction with BioMarin's GAAP information enhances investors' and analysts' ability to meaningfully compare the Company's results from period to period and to its forward looking guidance, and to identify operating trends in the Company's principal business. BioMarin also uses Non-GAAP Income (Loss) internally to understand, manage and evaluate its business and to make operating decisions, and compensation of executives is based in part on this measure.
Non-GAAP Income (Loss) and its components are not meant to be considered in isolation, as a substitute for, or superior to comparable GAAP measures and should be read in conjunction with the consolidated financial information prepared in accordance with GAAP. Investors should note that the Non-GAAP information is not prepared under any comprehensive set of accounting rules or principles and does not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. Investors should also note that these Non-GAAP measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its Non-GAAP measures; likewise, the Company may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP measures. Because of the non-standardized definitions, the Non-GAAP measure as used by BioMarin in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
The following table presents the reconciliation of GAAP Net Loss to Non-GAAP Income:
Reconciliation of GAAP Net Loss to Non-GAAP Income
(In millions of U.S. dollars)
(unaudited)
Three Months Ended Nine Months Ended
Year Ending
September 30, September 30,
December 31, 2018
2018 2017 2018 2017
Guidance
---
GAAP Net Loss $
(12.6) $
(12.5) $
(73.6) $
(65.7)
$(115.0) - $(165.0)
Interest expense, net 5.8 6.9 18.8 21.0
25.0 - 35.0
Benefit from income taxes (6.8) (8.1) (25.8) (24.8)
(40.0) - 0.0
Depreciation expense 18.6 13.3 48.1 36.9
50.0 - 60.0
Amortization expense 7.6 7.6 22.7 22.7 30.0
Stock-based compensation expense 37.1 35.9 112.3 106.7
150.0 - 170.0
Contingent consideration expense 11.0 (3.8) 19.3 3.4
20.0 - 30.0
Gain on sale of intangible assets (20.0) (20.0)
Royalty and other revenues (31.5) (31.5)
n/a
Non-GAAP Income $
60.7 $
7.8 $
101.8 $
68.7
$100 - $140
===
The following reconciliation of the GAAP reported to the Non-GAAP information provides the details of the effects of the Non-GAAP adjustments on certain components of the Company's operating results for each of the periods presented.
Reconciliation Of Certain GAAP Reported Information To Non-GAAP Information
(In millions of U.S. dollars)
(Unaudited)
Three Months Ended September 30,
2018 2017
Adjustments Adjustments
Interest, Stock-Based Interest, Stock-Based
Taxes, Compensation, Taxes, Compensation,
Depreciation Contingent Depreciation Contingent
and Consideration and Consideration
Amortization and Other Amortization and Other
GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP
Reported Reported
Royalty and other revenues $
5.4
$
$ $
5.4 $
35.4
$ $
(31.5) $
3.9
Cost of sales 78.9 (4.0) 74.9 59.5 (3.0) 56.5
Research and development 161.4 (7.0) (14.3) 140.1 154.1 (7.6) (13.8) 132.7
Selling, general and administrative 148.6 (11.6) (18.8) 118.2 130.5 (5.7) (19.1) 105.7
Intangible asset amortization 18.6 (7.6) (11.0) 3.8 (7.6) 3.8
and contingent consideration
Gain on sale of intangible assets
Interest expense, net (5.8) 5.8 (6.9) 6.9
Benefit from income taxes (6.8) 6.8 (8.1) 8.1
GAAP Net Loss/Non-GAAP Income (12.6) 25.2 48.1 60.7 (12.5) 19.7 0.6 7.8
Nine Months Ended September 30,
2018 2017
Adjustments Adjustments
Interest, Stock-Based Interest, Stock-Based
Taxes, Compensation, Taxes, Compensation,
Depreciation Contingent Depreciation Contingent
and Consideration and Consideration
Amortization and Other Amortization and Other
GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP
Reported Reported
Royalty and other revenues $
14.8
$
$ $
14.8 $
38.5
$ $
(31.5) $
7.0
Cost of sales 240.2 (10.4) 229.8 165.8 (7.8) 158.0
Research and development 520.9 (25.4) (43.1) 452.4 442.1 (20.2) (40.0) 381.9
Selling, general and administrative 440.2 (22.7) (58.8) 358.7 394.1 (16.7) (58.9) 318.5
Intangible asset amortization 42.0 (22.7) (19.3) 26.1 (22.7) (3.4)
and contingent consideration
Gain on sale of intangible assets (20.0) 20.0
Interest expense, net (18.8) 18.8 (21.0) 21.0
Benefit from income taxes (25.8) 25.8 (24.8) 24.8
GAAP Net Loss/Non-GAAP Income (73.6) 63.8 111.6 101.8 (65.7) 55.8 78.6 68.7
(Loss)
View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-announces-third-quarter-2018-results-300737878.html
SOURCE BioMarin Pharmaceutical Inc.
